Breaking it down, net revenue from our Rx segment for the full year was $65,200,000 compared to $73,800,000 in fiscal 2023, a decrease of $8,600,000 Within Rx, we saw growth in our ADHD products of 8% in the second half of the fiscal year. For the full year, our ADHD portfolio, which comprised 89% of Rx net revenue, saw a 23% increase to $57,800,000 compared to the prior year period of $46,900,000 The growth in ADHD was offset by a decrease in our pediatric portfolio with full net year revenue coming in at $7,300,000 compared to $25,400,000 last year, a decrease of $18,100,000 As Josh indicated, the pediatric change is due to payer changes that impacted prescriptions, which we have communicated in detail over the past few quarters. And as Josh also pointed out, we are now starting to see signs of improvement. Looking specifically at the 4th quarter, Rx segment revenue was $14,600,000 compared to $23,300,000 in Q4 of last year. The change was primarily due to a decrease in pediatric sales mentioned and to a lesser extent a decrease in ADHD net revenues as the ADHD gross to net adjustments reflected a more normal status in the Q4 of 2024 as compared to 2023.